A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia

NCT01384201

Gastric Intestinal Metaplasia

COMPLETED

Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis

NCT04840056

Gastric Cancer Intestinal Metaplasia Atrophic Gastritis

RECRUITING

Endoscopic Full Thickness Resection for Gastric GIST

NCT04198337

Gastric GIST

RECRUITING NA

Study On Safety Of Endoscopic Resection For 2-5cm Gastric Gastrointestinal Stromal Tumor

NCT04751591

Gastric GIST

UNKNOWN NA

Aberrant DNA Methylation to Predict Metachronous Gastric Neoplasms

NCT04830618

Metachronous Neoplasm Gastric Cancer Gastric Neoplasm +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A retrospective clinical records review of patients diagnosed with gastrointestinal stromal tumour (GIST) in the two tertiary centres in Singapore i.e. Singapore General Hospital and National University Hospital.

Gastrointestinal tumours are the most common soft-tissue tumours of the gastrointestinal tracts. Remarkable progress has been made during the last several years in the diagnosis and treatment of GIST. Understanding of the molecular pathogenesis of GIST which is linked to deregulated KIT tyrosine-kinase activity has improved diagnosis, such that GIST is now more frequently and specifically identified. More importantly, systemic tyrosine kinase inhibitor, imatinib, has been used successfully in the treatment of GIST patients with advanced or unresectable disease.

GIST has been reviewed in the Western literature but there is a lack of Asian data. The review will help us to better understand the disease in our population.Furthermore we will also examine several unresolved issues in the Western literature by looking into our local data. These include required duration of imatinib therapy, role of imatinib in the adjuvant setting (application of chemotherapy after macroscopically complete removal of tumour) and role of combination therapies.

The medical records of all patients diagnosed with the disease at the two centres will be reviewed.

Analysis of the results aims to:

1. to compare the characteristics of the GIST (epidemiology, site, morphology, immunohistochemistry profile) in our centres compared to the well-published literature.
2. to compare the treatment regimen and results of our centres compared to others
3. to review the role of chemotherapy in the adjuvant settings in the centres.